Collegium Pharmaceutical Future Growth

Future criteria checks 2/6

Collegium Pharmaceutical's revenue is forecast to decline at 7.3% per annum while its annual earnings are expected to grow at 15.1% per year. EPS is expected to grow by 10.5% per annum.

Key information

15.1%

Earnings growth rate

10.5%

EPS growth rate

Pharmaceuticals earnings growth	23.5%
Revenue growth rate	-7.3%
Future return on equity	n/a
Analyst coverage	Good
Last updated	10 May 2024

Recent future growth updates

Recent updates

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30

Sizing Up Collegium Pharmaceuticals

Oct 04

Earnings and Revenue Growth Forecasts

NasdaqGS:COLL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	569	174	286	346	5
12/31/2025	597	148	319	343	6
12/31/2024	583	121	351	356	6
3/31/2024	567	93	308	309	N/A
12/31/2023	567	48	274	275	N/A
9/30/2023	547	9	266	268	N/A
6/30/2023	537	-11	235	236	N/A
3/31/2023	525	-29	176	177	N/A
12/31/2022	464	-25	123	124	N/A
9/30/2022	362	-43	93	94	N/A
6/30/2022	314	-35	67	69	N/A
3/31/2022	273	43	56	58	N/A
12/31/2021	277	72	102	104	N/A
9/30/2021	326	104	87	90	N/A
6/30/2021	326	107	102	107	N/A
3/31/2021	321	42	115	121	N/A
12/31/2020	310	27	-280	94	N/A
9/30/2020	308	18	-286	87	N/A
6/30/2020	302	0	-313	59	N/A
3/31/2020	299	-13	-341	30	N/A
12/31/2019	297	-23	21	28	N/A
9/30/2019	296	-11	47	54	N/A
6/30/2019	293	-22	81	90	N/A
3/31/2019	291	-30	123	131	N/A
12/31/2018	280	-39	145	169	N/A
9/30/2018	218	-66	91	114	N/A
6/30/2018	160	-62	39	59	N/A
3/31/2018	90	-70	-34	-14	N/A
12/31/2017	28	-75	N/A	-67	N/A
9/30/2017	19	-85	N/A	-77	N/A
6/30/2017	7	-98	N/A	-84	N/A
3/31/2017	4	-102	N/A	-87	N/A
12/31/2016	2	-94	N/A	-75	N/A
9/30/2016	0	-76	N/A	-61	N/A
6/30/2016	N/A	-59	N/A	-48	N/A
3/31/2016	N/A	-40	N/A	-31	N/A
12/31/2015	N/A	-20	N/A	-22	N/A
9/30/2015	N/A	-15	N/A	-20	N/A
6/30/2015	N/A	-13	N/A	-18	N/A
3/31/2015	N/A	-12	N/A	-16	N/A
12/31/2014	N/A	-21	N/A	-18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLL's forecast earnings growth (15.1% per year) is above the savings rate (2.4%).

Earnings vs Market: COLL's earnings (15.1% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: COLL's earnings are forecast to grow, but not significantly.

Revenue vs Market: COLL's revenue is expected to decline over the next 3 years (-7.3% per year).

High Growth Revenue: COLL's revenue is forecast to decline over the next 3 years (-7.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if COLL's Return on Equity is forecast to be high in 3 years time

Collegium Pharmaceutical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

Price target increased by 13% to US$37.75

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Price target decreased by 8.3% to US$33.25

Recent updates

Independent Director notifies of intention to sell stock

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Announces CEO Transition

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical, Inc. to Report Q1, 2024 Results on May 09, 2024

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Collegium Pharmaceutical Q4: The Beat Goes On

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS exceeds analyst expectations

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Executive VP & Chief Commercial Officer notifies of intention to sell stock

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Price target increased by 13% to US$37.75

President notifies of intention to sell stock

Executive VP exercised options and sold US$253k worth of stock

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 8.3% to US$33.25

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & CFO notifies of intention to sell stock

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 12% to US$36.00

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target increased to US$34.00

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Co-Founder & Chairman notifies of intention to sell stock

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Co-Founder & Chairman exercised options and sold US$1.3m worth of stock

President notifies of intention to sell stock

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Executive VP & CFO notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$31.40

Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Collegium Pharmaceutical, Inc. Appoints Neil McFarlane to its Board of Directors

Consensus EPS estimates fall by 16%

Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Year 2022

Collegium Pharmaceutical, Inc. Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation